London, UK – In a significant scientific breakthrough that promises to redefine the landscape of ovarian cancer treatment, researchers at King’s College London have unveiled the intricate mechanism by which a novel type of antibody therapy reactivates patients’ own immune cells to fiercely combat the disease. This groundbreaking research, spearheaded by the group of Professor Sophia Karagiannis, sheds critical light on the responses of patients receiving this pioneering therapy and offers a beacon of hope for those battling one of the most challenging cancers.
Published today in the prestigious journal Nature Communications, the findings detail how an engineered IgE antibody, named MOv18, uniquely reverses the immune suppression orchestrated by ovarian tumours, effectively galvanising different groups of immune cells to launch a sustained attack. The study was a collaborative effort, supported by major funders including Cancer Research UK, the Medical Research Council, and Breast Cancer Now.
For decades, the fight against ovarian cancer has been fraught with challenges, primarily due to its late diagnosis and propensity for resistance to conventional therapies. This new development, centering on an antibody distinct from the commonly used IgG class, marks a pivotal shift in therapeutic strategy, offering a fresh perspective on how the body’s own defence mechanisms can be harnessed against solid tumours.
The Silent Scourge: Ovarian Cancer’s Enduring Challenge
Ovarian cancer remains a formidable adversary in oncology. Often referred to as a "silent killer" due to its vague symptoms and late-stage diagnosis, it is the sixth most common cancer among women in the UK, with survival rates significantly lower than many other cancers. Globally, it claims the lives of hundreds of thousands each year. Current treatment modalities typically involve aggressive surgery, chemotherapy, and sometimes targeted therapies. While these approaches can be effective initially, many patients experience recurrence, often with tumours that have developed resistance to previous treatments, leaving them with limited options.
The insidious nature of ovarian cancer lies not only in its asymptomatic progression but also in its ability to manipulate its surrounding environment – the tumour microenvironment (TME) – to evade detection and destruction by the immune system. Tumours often create an immunosuppressive "shield," disarming key immune cells that would otherwise recognise and eliminate cancerous threats. Overcoming this immune suppression has been a central, yet largely unmet, challenge in developing effective immunotherapies for ovarian cancer.
Immunotherapy: A New Frontier, and the IgE Revelation
Immunotherapy, a revolutionary approach that empowers the body’s immune system to fight cancer, has transformed the treatment landscape for several malignancies. A cornerstone of immunotherapy involves antibody treatments, which are engineered proteins designed to specifically target cancer cells or immune checkpoints. Almost all clinically approved antibody treatments for cancer are derived from a class of antibodies called immunoglobulin G, or IgG. These IgG antibodies work by activating immune cells circulating in the bloodstream, triggering responses that can shrink tumours.
However, despite the success of IgG-based immunotherapies in certain cancers, their efficacy against ovarian cancer has been notably limited. Researchers have long grappled with why these seemingly powerful treatments fall short in this particular disease. The answer, it turns out, may lie in a completely different class of antibodies: immunoglobulin E, or IgE.
IgE antibodies are perhaps best known for their critical, albeit sometimes inconvenient, roles in allergic reactions, where they trigger potent immune responses against harmless substances like pollen or peanuts. Less widely appreciated, but equally vital, is their function in stimulating immune cells to combat parasitic infections. Crucially, unlike IgG antibodies which primarily engage immune cells in the blood, IgE antibodies exhibit an exceptionally tight binding affinity to specific receptors found on immune cells residing within tissues. This unique property, the King’s College London team hypothesised, could be harnessed to activate immune cells directly within the solid tumour microenvironment, where ovarian cancer cells thrive and immune suppression is most pronounced.
Professor Sophia Karagiannis’s team at King’s College London stands at the forefront of this pioneering research, being the first in the world to successfully develop a therapeutic antibody from the IgE class for cancer treatment. Their groundbreaking work has focused on leveraging these potent, tissue-specific immune-boosting activities of IgE against solid cancers, offering a novel paradigm for immunotherapy.
Pioneering MOv18 IgE: From Conception to Clinic
The journey to develop MOv18 IgE began with a deep understanding of IgE’s unique biological properties. Recognising its unparalleled ability to bind tightly to receptors on tissue-resident immune cells, the King’s researchers embarked on a mission to engineer an IgE antibody specifically designed to target ovarian cancer cells. The chosen candidate, MOv18, was carefully selected for its specificity and potential to deliver a potent anti-cancer signal directly to the tumour site.
The team’s initial investigations focused on MOv18 IgE’s capacity to activate immune cells derived from ovarian cancer patients and its influence on the tumour’s intricate environment. What they discovered was truly remarkable: MOv18 IgE operates through a distinctive mechanism, effectively dismantling the immune system’s suppression imposed by the tumour. It achieves this by activating diverse groups of immune cells, directing them to turn the tide against the cancer.
This innovative IgE treatment rapidly moved from preclinical studies to human trials, demonstrating its significant potential. MOv18 IgE has already yielded promising results in a phase Ia clinical trial, meticulously designed and executed by the King’s researchers at the National Institute for Health and Care Research (NIHR) Guy’s and St Thomas’ Clinical Research Facility, in collaboration with Cancer Research UK’s Centre for Drug Development.
In an early, compelling demonstration of its efficacy, the trial observed that even at low doses, MOv18 IgE successfully shrank the tumour of a patient with ovarian cancer who had previously shown no response to conventional therapies. This single patient’s positive outcome, though preliminary, served as a powerful validation of the IgE concept and spurred the team to delve deeper into the precise mechanisms underlying the antibody’s anti-cancer activity within the complex immune environment of ovarian cancer.
Unveiling the Mechanism: The Nature Communications Study
The imperative to understand how MOv18 IgE works was paramount. Moving beyond observed clinical effects, the researchers embarked on a comprehensive, multidisciplinary study to dissect the biological underpinnings of the antibody’s action. This detailed investigation, published in Nature Communications, was crucial for optimising the therapy, identifying potential biomarkers for patient selection, and exploring its broader application.
The study was a testament to collaborative science, involving colleagues from Guy’s and St Thomas’ NHS Foundation Trust, the Medical University of Vienna, Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, and SeromYx Systems, Inc., alongside the core team at King’s. Together, they meticulously examined how MOv18 IgE interacts with different populations of immune cells within ovarian cancer patients.
Targeting the Tumor Microenvironment’s Master Manipulators: Macrophages
The primary focus of their investigation centred on macrophages, a type of immune cell traditionally known for its role in fighting infections and clearing cellular debris. However, in the context of cancer, macrophages often undergo a sinister transformation. Instead of functioning as immune defenders, they can be "corrupted" by the tumour microenvironment, losing their ability to trigger an immune response and becoming reprogrammed to actively support tumour growth and spread. These "tumour-associated macrophages" (TAMs) are key players in the immune-suppressive shield that ovarian cancers erect.
Previous research conducted in animal models had hinted that MOv18 IgE could activate these corrupted macrophages, redirecting them from being tumour-supporters to tumour-fighters. To validate this crucial hypothesis in a human context, the team devised elegant experiments. They first collected macrophages from healthy donors and then exposed them to cancerous fluid samples obtained from the peritoneal cavity – the main site of ovarian cancer spread – of patients suffering from the disease. In parallel, they directly isolated macrophages from these patient-derived cancerous fluid samples, all collected from Guy’s and St Thomas’ NHS Foundation Trust.
In both experimental setups, the researchers consistently observed that ovarian cancer fluid profoundly suppressed the normal immune activity of macrophages. This confirmed the tumour’s ability to hijack these critical immune cells. However, the pivotal discovery came when they introduced MOv18 IgE. They found that the IgE antibody could specifically bind to and activate these previously suppressed macrophages, compelling them to effectively kill ovarian cancer cells.
The T-Cell Connection: Reversing Immunosuppression
The impact of MOv18 IgE extended beyond macrophages. Through this activation, the IgE antibody achieved another critical feat: it reversed the suppressive effect that ovarian cancer macrophages exerted on other vital immune cells known as T cells. T cells are widely recognised as essential components of the adaptive immune system, playing a key role in orchestrating and maintaining long-term, memory-based immune responses against cancer. By liberating T cells from macrophage-mediated suppression, MOv18 IgE effectively activated a broader, more robust anti-cancer immune response.
Dr. Gabriel Osborn, who conducted this pivotal research during his PhD studies at King’s College London, articulated the profound implications of these findings: "We found that in patients, ovarian cancer re-programmed macrophages away from normal immune activation. Instead, they formed an immunosuppressive web in association with T cells, that could restrict anti-cancer immunity in patients. MOv18 IgE however induced patient macrophages to kill cancer cells and undergo a highly inflammatory activation, which reversed their suppressive effects on T cells. This study adds important patient-level information to support what we previously observed for MOv18 IgE in the laboratory and reveals, for the first time, that IgE-driven macrophage stimulation can activate the wider tumour immune system."
Clinical Validation: Biopsy Analysis from Trial Patients
To bridge the gap between laboratory observations and real-world patient outcomes, the team took their investigation a step further. They analysed tumour biopsies from two patients who had participated in the Phase Ia clinical trial. For each patient, one biopsy was collected before treatment with MOv18 IgE, and a second biopsy was taken after treatment.
The analysis of these precious samples provided compelling clinical validation of the laboratory findings. Post-treatment biopsies revealed a marked increase in the numbers of both macrophages and T cells present within the tumour environment. This direct human evidence strongly indicated that these two critical groups of immune cells are indeed mobilised and play a key role in the anti-tumour activity observed with MOv18 IgE, solidifying the proposed mechanism of action.
Expert Perspectives and the Road Ahead
The publication of these findings represents a major milestone, but the researchers emphasise that this is just one step in a longer journey towards bringing new treatments to patients.
Professor Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy at King’s College London and the senior author of the study, highlighted the overarching importance of mechanistic understanding. "Understanding the biology of how a treatment works is essential for bringing treatments closer to patients," she stated. "We found that immune cells which are otherwise inhibited in the ‘microenvironment’ of the tumour, are directed by IgE to target the cancer cells. While we are still progressing with clinical testing in patients, it is imperative that we continue in our quest towards understanding how MOv18 IgE, and a wider panel of IgE-based antibodies we are studying, harness the immune system in different groups of patients and cancer types." Her vision extends beyond MOv18, aiming to unlock the full therapeutic potential of the entire IgE antibody class.
Dr. Debra Josephs, a consultant medical oncologist at Guy’s and St Thomas’ NHS Foundation Trust and a co-author of the study, played a crucial role in the preclinical research that guided MOv18 IgE towards clinical testing. She underscored the clinical relevance of the findings: "Our focus is to deepen our understanding of the immune system and its interaction with cancer, with the goal of discovering better treatments for patients. During the preclinical development of MOv18 IgE we demonstrated the important role of activation and migration of tumour-associated macrophages into cancer lesions for this antibody treatment to be effective. This research marks an important next step in the development of MOv18 IgE by advancing our understanding of macrophage-mediated mechanisms, thus supporting the therapeutic potential of this novel antibody." Her insights from the clinical frontline are invaluable in translating scientific discovery into patient benefit.
Professor James Spicer, Professor of Experimental Cancer Medicine at King’s College London, consultant in medical oncology at Guy’s and St Thomas’ NHS Foundation Trust, and Chief Clinical Investigator of the MOv18 IgE Phase Ia trial, also a co-author, articulated the overarching clinical imperative. "We need to achieve better outcomes for our patients," he affirmed. "Clear progress is being made by studying the immune system and the environment in which the cancer grows. In our ongoing research we are striving to understand how we can capitalise on the power of IgE to develop novel effective treatments, which will complement established IgG antibody drugs used in the clinic." His perspective highlights the potential for IgE therapies to not only stand alone but also to synergise with existing treatments, expanding the arsenal against cancer.
Broader Implications and Future Directions
The implications of this research extend far beyond ovarian cancer. The success of MOv18 IgE in reactivating suppressed immune cells within a solid tumour microenvironment opens up exciting avenues for exploring IgE-based therapies in other hard-to-treat solid cancers that also employ similar immune evasion strategies. Cancers of the breast, lung, and pancreas, which often present significant challenges to immunotherapy due to their immunosuppressive microenvironments, could potentially benefit from this novel approach.
Future research will undoubtedly focus on several key areas:
- Expanding Clinical Trials: Larger Phase Ib/II trials are essential to further assess the safety, efficacy, and optimal dosing of MOv18 IgE in a broader patient population with ovarian cancer.
- Biomarker Identification: Identifying predictive biomarkers will be crucial for selecting patients most likely to respond to IgE therapy, moving towards a more personalised medicine approach.
- Combination Therapies: Exploring combinations of MOv18 IgE with existing immunotherapies, chemotherapy, or targeted agents could lead to enhanced anti-tumour responses and improved patient outcomes.
- Investigating Other IgE Antibodies: Professor Karagiannis’s team is actively studying a "wider panel of IgE-based antibodies" for different cancer types, suggesting a new wave of IgE therapeutics is on the horizon.
This work underscores the importance of fundamental research in immunology and cancer biology, and how a deep understanding of basic biological mechanisms can lead to transformative clinical applications. The collaborative spirit among academic institutions, healthcare providers, and funding bodies has been instrumental in bringing this innovative therapy to the cusp of changing patient lives.
The authors also acknowledge crucial support from the Cancer Research UK City of London Centre and the King’s Health Partners Centre for Translational Medicine, highlighting the vital network of collaboration and funding that underpins such groundbreaking scientific advancements. As research continues, the hope is that IgE antibodies like MOv18 will soon offer a powerful new weapon in the ongoing battle against cancer, offering renewed hope to patients and their families worldwide.
About the Author
